The effect of intravitreal bevacizumab (Avastin&reg;) on ocular pulse amplitude in neovascular age-related macular degeneration

Código QR

The effect of intravitreal bevacizumab (Avastin&reg;) on ocular pulse amplitude in neovascular age-related macular degeneration

Ehud Rechtman1, Ingeborg Stalmans2, Joseph Glovinsky1, Christophe Breusegem2, Joseph Moisseiev1, Joachim Van Calster2, Alon Harris31Goldschleger Eye Institute, Sheba Medical Center, Ramat Gan, Israel; 2Department of Ophthalmology, University Hospitals Leuven, Leuven, Belgium; 3Department of Ophthalm...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ehud Rechtman, Ingeborg Stalmans, Joseph Glovinsky, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/6639e7b2bd77417e9cb3d44df874ab2b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Is monthly retreatment with intravitreal bevacizumab (Avastin&reg;) necessary in neovascular age-related macular degeneration?
por: Nicola G Ghazi, et al.
Publicado: (2010)

Pharmacokinetics of intravitreal bevacizumab (Avastin&reg;) in rabbits
por: Sinapis C, et al.
Publicado: (2011)

Bevacizumab (Avastin&reg;) for the management of anterior chamber neovascularization and neovascular glaucoma
por: Dimitrios Brouzas, et al.
Publicado: (2009)

Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
por: Juan Carlos Mesa Guti&eacute;rrez, et al.
Publicado: (2008)

Massive choroidal hemorrhage after intravitreal administration of bevacizumab (Avastin&reg;) for AMD followed by controlateral sympathetic ophthalmia
por: Dimitrios Brouzas, et al.
Publicado: (2009)

Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration
por: Mamdouh M Kabeel, et al.
Publicado: (2008)

Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration
por: P William Conrad, et al.
Publicado: (2008)

Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization
por: Mansour AM, et al.
Publicado: (2012)

Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization
por: Ioannis D Ladas, et al.
Publicado: (2008)

VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF BRANCH RETINAL VEIN OCCLUSION
por: Saquib Naeem, et al.
Publicado: (2019)

Short-Term Outcomes After COVID-19-Related Treatment Interruption Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Bevacizumab
por: Allegrini D, et al.
Publicado: (2021)

Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab
por: Palejwala NV, et al.
Publicado: (2014)

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
por: Jia-Kang Wang, et al.
Publicado: (2018)

Histology of neovascular myopic macular degeneration
por: Shefali B. Jonas, et al.
Publicado: (2021)

Choroidal osteoma with choroidal neovascular membrane: Successful treatment with intravitreal bevacizumab
por: Neeraj Pandey, et al.
Publicado: (2010)

Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma
por: Marey HM, et al.
Publicado: (2011)

Effects of Intravitreous Aflibercept Injection in Pachychoroid Neovasculopathy: Comparison with Typical Neovascular Age-Related Macular Degeneration
por: Elfandi S, et al.
Publicado: (2021)

Timing of neovascular regression in eyes with high-risk proliferative diabetic retinopathy without macular edema treated initially with intravitreous bevacizumab
por: Shakarchi FI, et al.
Publicado: (2018)

Intravitreal ranibizumab for symptomatic drusenoid pigment epithelial detachment without choroidal neovascularization in age-related macular degeneration
por: Roberto Gallego-Pinazo, et al.
Publicado: (2011)

Anterior segment changes following intravitreal bevacizumab injection for treatment of neovascular glaucoma
por: Canut MI, et al.
Publicado: (2011)

Posterior capsule opacification and neovascularization treated with intravitreal bevacizumab and Nd:YAG capsulotomy
por: Grimelda Yuriana S&aacute;nchez-Castro, et al.
Publicado: (2008)

Long-term success of intravitreal bevacizumab for choroidal neovascularization associated with choroidal osteoma
por: Kubota-Taniai M, et al.
Publicado: (2011)

Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis.
por: Wei Wang, et al.
Publicado: (2014)

Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates
por: Jeon S, et al.
Publicado: (2014)

Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye
por: Hahn P
Publicado: (2014)

Foveal atrophy and macular hole formation following intravitreal ranibizumab with/without photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration
por: Pukhraj Rishi, et al.
Publicado: (2011)

Revisiting the Utility of Dilated Fundus Exams in Patients with Neovascular Age-Related Macular Degeneration Receiving Regular Intravitreal Injections
por: Antaki F, et al.
Publicado: (2021)

Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration
por: Luis Arias, et al.
Publicado: (2010)

Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy
por: Hidetaka Matsumoto, et al.
Publicado: (2021)

Radiation therapy for neovascular age-related macular degeneration
por: Robert Petrarca, et al.
Publicado: (2011)

Hemiretinal vein occlusion with macular hemorrhage and edema treated with intravitreal bevacizumab
por: Yalamanchi S, et al.
Publicado: (2011)

Proteins from Avastin® (bevacizumab) show tyrosine nitrations for which the consequences are completely unclear.
por: Jia Wan, et al.
Publicado: (2012)

Real-World Outcomes of Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration: A Large-Scale Postmarketing Surveillance in Korea
por: Ryu G, et al.
Publicado: (2021)

A matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extraction
por: Fischer N, et al.
Publicado: (2013)

Correlation between ocular perfusion pressure and ocular pulse amplitude in glaucoma, ocular hypertension, and normal eyes
por: Figueiredo BP, et al.
Publicado: (2013)

Long-term outcomes of intravitreal injection of bevacizumab for choroidal neovascularization associated with choroidal osteoma
por: Yoshikawa T, et al.
Publicado: (2015)

Glaucoma drainage device implantation with adjunctive intravitreal bevacizumab in neovascular glaucoma: 3-year experience
por: Noor NA, et al.
Publicado: (2017)

Lucentis&reg; using Visudyne&reg; study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration
por: Eric Chen, et al.
Publicado: (2010)

Treatment of neovascular age-related macular degeneration: Current therapies
por: Albert J Augustin, et al.
Publicado: (2009)

Treatment of neovascular age-related macular degeneration in patients with diabetes
por: Michael Cummings, et al.
Publicado: (2008)